The effect of d-2(p-aminophenyl)-2-phenylethylamine (SK&F-12185) in Cushing's syndrome associated with adrenocortical carcinoma.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000305:Adrenal Cortex Hormones / Q000096:biosynthesis*; D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000188:drug therapy*; D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism*; D000309:Adrenal Insufficiency / Q000139:chemically induced; D002277:Carcinoma; D002986:Clinical Trials as Topic; D003480:Cushing Syndrome / Q000150:complications / Q000188:drug therapy*; D003864:Depression, Chemical; D005260:Female; D006801:Humans; D008875:Middle Aged; D009318:Natriuresis; D010627:Phenethylamines / Q000627:therapeutic use*; D011278:Pregnanes / Q000652:urine; D014882:Water-Electrolyte Balance
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D000305:Adrenal Cortex Hormones; D010627:Phenethylamines; D011278:Pregnanes